Encoded Therapeutics Raises $275M Series F for Dravet Syndrome Gene Therapy
- Encoded Therapeutics closed a $275 million Series F financing round, co-led by GV and an undisclosed healthcare investor, with participation from ARCH Venture Partners, Braidwell, Farallon, Illumina Ventures, Invus, Janus Henderson, Matrix Capital, RTW Investments, SoftBank Vision Fund 2, Venrock and others.
- Proceeds will fund pivotal and age-expansion studies of ETX101, an AAV9-delivered gene-regulation therapy designed to restore SCN1A gene expression in children with SCN1A-positive Dravet syndrome, a severe and treatment-resistant form of pediatric epilepsy.
- Interim data from the Phase 1/2 POLARIS trial, presented at the European Epilepsy Congress, showed encouraging reductions in seizure frequency and gains on developmental measures among treated children.
- The financing will also support manufacturing scale-up and advancement of a second pipeline program, ETX301, targeting post-amputation neuroma pain, toward an IND filing in 2027.
Two hundred seventy-five million is a lot of private capital for a single indication, and it's flowing into gene regulation, not editing or replacement — investors betting that tunable, reversible expression control beats permanent genomic rewrites for a pediatric CNS target. The POLARIS interim data give Encoded first-mover clinical standing in SCN1A-directed Dravet therapy, ahead of gene-replacement and antisense rivals still in earlier stages. The size and syndicate here — GV, ARCH, SoftBank Vision Fund 2 — also reads as a financing-market tell: late-stage private mega-rounds are absorbing capital that might otherwise chase an IPO, a sign the window stays selectively closed. Earmarking part of the raise for ETX301, an unrelated pain asset, is a platform bet — diversification that could dilute focus on the pivotal Dravet push.